• Major stakeholder group member involved in working with the Federal Government on revisions to the Intravenous Chemotherapy Supply Program (ICSP) which was finally implemented in December 2011. Significant headway was made in terms of the number of drugs available as streamlined authorities, number of repeats etc. The area of electronic scripting/charting requires continued efforts.
  • Planning of a study of cancer treatment in Australian private practice in collaboration with the Australian Private Hospitals Association and Private Healthcare Australia, and supported by Roche Products. This is in addition to a prospective survey of approx. 1000 newly diagnosed cancer patients treated at approx. 10 private practices Australia-wide – survey to be concluded soon in preparation for presentation/publication .
  • Involvement in working groups tasked with resolving various oncology ‘drugs issues’.
  • Support of the Australian Diagnostic Imaging Association (ADIA) in the campaign for indexation and increased funding of diagnostic imaging rebates.
  • Convenor of specialist Medical Oncology and Haematology training programs.
  • Contributor to the Australian Medical Oncologist Workforce Study, 2009.
  • Contributor to reviews on ‘Supply and/or remuneration arrangements for PBS medicines and drugs listed under Section 100’, also ‘funding for pathology services’.
  • Delivery of Annual Scientific Meetings for PCPA membership.
May 9, 2019
Private oncologists reject PM claims of ‘fee hikes’ for cancer patients
behalf of Australian cancer patients and their families
The ‘Cancer Care, No Gaps’ Journey. Clinical trials – more patients, less cost.
Enjoy all the benefits of membership
With a strong leadership group and a potential membership base of all private oncologists and haematologists, PCPA represents a critical group of specialists in the cancer care service spectrum.